SAN DIEGO, Oct. 26, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that it will present three posters highlighting both new clinical findings and preclinical research accomplishments at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26 - 30, 2017 in Philadelphia, Pennsylvania.
Paul Maffuid, Ph.D., Executive Vice President of Research and Development of MabVax, stated, "We look forward to sharing the significant progress we have made through these clinical and preclinical investigations. We will report new clinical data from our ongoing Phase 1 clinical trial and report on our most advanced preclinical program that demonstrates our growing expertise in the development of fully human antibodies targeting carbohydrate antigens expressed on many solid tumor cancers."
The Company will present the following posters during the meeting:
Presenting Author: Paul Maffuid, Ph.D., Executive Vice President Research and Development, MabVax Therapeutics
Title: Using CA19-9 as a translational biomarker for sLea targeted agents MVT-5873 and MVT-1075 in cancer
Date & Time: Saturday, October 28, 2017 at 12:30 PM
Session: Poster Session A: Biomarkers
Location: Hall E, Pennsylvania Convention Center
Poster No.: 62
Abstract No.: A062
The poster summarizes preclinical development activities including a survey of CA19-9 positive cancers in patient tissue microarrays and patient sera samples treated with the anti-CA19-9 antibody MVT-5873 with potential utility as a translational biomarker.
Presenting Author: Paul Maffuid, Ph.D., Executive Vice President Research and Development, MabVax Therapeutics
Title: Preliminary Phase 1 data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer
Date & Time: Sunday, October 29, 2017 at 12:30 PM
Session: Late Breaking Poster Session B: Therapeutic Agents: Biological
Location: Hall E, Pennsylvania Convention Center
Poster No.: LB-25
Abstract No.: LB-B25
The poster summarizes interim data from the ongoing Phase 1 trial of MVT-5873 used as a single agent and in combination with a first line therapy in newly diagnosed patients with CA19-9 positive pancreatic cancer.
Presenting Author: G. Jonah Rainey, Ph.D., Executive Director Antibody Research, MabVax Therapeutics
Title: A therapeutic antibody candidate against the broadly expressed Tn and sTn carbohydrate cancer antigens
Date & Time: Sunday, October 29, 2017 at 12:30 PM
Session: Poster Session B: Therapeutic Agents: Biological
Location: Hall E, Pennsylvania Convention Center
Poster No.: 104
Abstract No.: B104
The poster summarizes the discovery, optimization, and target validation for the Company's fully human antibodies targeting the Thomsen-nouveau (Tn) and the sialyl Tn (sTn) carbohydrate antigens for patients with ovarian and breast cancers.
About MabVax
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety, specificity for the target and a potential efficacy signal. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075. For additional information, please visit the Company's website, www.mabvax.com.
Forward Looking Statements:
This press release on announcing the business outlook for the Company contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's clinical trials and product development pipeline. We have no assurance that the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Investor Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jtc@jenenethomascommunications.com
SOURCE MabVax Therapeutics Holdings, Inc.